Dimerix Gains New Human Evidence Supporting DMX-200 Kidney Disease Target
Dimerix gains human evidence linking CCR2 activity to poorer FSGS outcomes, strengthening the rationale for DMX-200 as its Phase 3 ACTION3 trial progresses.
Dimerix gains human evidence linking CCR2 activity to poorer FSGS outcomes, strengthening the rationale for DMX-200 as its Phase 3 ACTION3 trial progresses.